Terokai is the trade name for erlotinib hydrochloride tablets, and Erythroxa is the trade name for gefitinib tablets, with the main differences being in the stage of administration, price, and clinical survival. Both drugs are clinically used in the treatment of lung cancer targeted drugs. 1. Medication stage: Erlotinib hydrochloride tablets are mainly used in the treatment of non-small cell lung cancer, including first-line treatment, maintenance treatment, or second-line and above treatment after having received at least one previous chemotherapy progression. Gefitinib tablets, on the other hand, are mainly indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have been treated with chemotherapy. 2. Price: Erlotinib Hydrochloride Tablets are more expensive, and in comparison, the cost of using Erlotinib Hydrochloride Tablets is higher than that of Gefitinib Tablets. 3. Survival: Clinical trials have shown that erlotinib hydrochloride tablets are better than gefitinib tablets in terms of patient survival. According to the results of clinical trials, in the long run, the use of Erlotinib Hydrochloride Tablets in the treatment should be a relatively better choice, but taking into account the relatively high price of Erlotinib Hydrochloride Tablets, the specific treatment of medication should be in accordance with the requirements of the doctor and the actual situation, can not be blindly used to avoid delaying the condition.